These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 38496534)
1. A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant. Euliano EM; Pogostin BH; Agrawal A; Yu MH; Baryakova TH; Graf TP; Hartgerink JD; McHugh KJ bioRxiv; 2024 Mar; ():. PubMed ID: 38496534 [TBL] [Abstract][Full Text] [Related]
2. Gold Nanoparticles Coimmobilized with Small Molecule Toll-Like Receptor 7 Ligand and α-Mannose as Adjuvants. Shinchi H; Yamaguchi T; Moroishi T; Yuki M; Wakao M; Cottam HB; Hayashi T; Carson DA; Suda Y Bioconjug Chem; 2019 Nov; 30(11):2811-2821. PubMed ID: 31560198 [TBL] [Abstract][Full Text] [Related]
3. Conjugation of a Small-Molecule TLR7 Agonist to Silica Nanoshells Enhances Adjuvant Activity. Huang CH; Mendez N; Echeagaray OH; Weeks J; Wang J; Vallez CN; Gude N; Trogler WC; Carson DA; Hayashi T; Kummel AC ACS Appl Mater Interfaces; 2019 Jul; 11(30):26637-26647. PubMed ID: 31276378 [TBL] [Abstract][Full Text] [Related]
4. Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities. Shinchi H; Yuki M; Yamauchi T; Niimura M; Wakao M; Cottam HB; Hayashi T; Carson DA; Moroishi T; Suda Y ACS Appl Bio Mater; 2021 Mar; 4(3):2732-2741. PubMed ID: 35014312 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. Shinchi H; Crain B; Yao S; Chan M; Zhang SS; Ahmadiiveli A; Suda Y; Hayashi T; Cottam HB; Carson DA Bioconjug Chem; 2015 Aug; 26(8):1713-23. PubMed ID: 26193334 [TBL] [Abstract][Full Text] [Related]
6. Glyco-Nanoadjuvants: Impact of Linker Length for Conjugating a Synthetic Small-Molecule TLR7 Ligand to Glyco-Nanoparticles on Immunostimulatory Effects. Shinchi H; Komaki F; Yuki M; Ohara H; Hayakawa N; Wakao M; Cottam HB; Hayashi T; Carson DA; Moroishi T; Suda Y ACS Chem Biol; 2022 Apr; 17(4):957-968. PubMed ID: 35353497 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands. Baba A; Wakao M; Shinchi H; Chan M; Hayashi T; Yao S; Cottam HB; Carson DA; Suda Y Bioorg Med Chem Lett; 2020 Feb; 30(3):126840. PubMed ID: 31864800 [TBL] [Abstract][Full Text] [Related]
9. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses. Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Dolzhikova IV; Stanhope-Baker P; Naroditsky BS; Gudkov AV; Logunov DY; Gintsburg AL PLoS One; 2016; 11(5):e0155650. PubMed ID: 27187797 [TBL] [Abstract][Full Text] [Related]
10. Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice. Goff PH; Hayashi T; He W; Yao S; Cottam HB; Tan GS; Crain B; Krammer F; Messer K; Pu M; Carson DA; Palese P; Corr M J Virol; 2017 Oct; 91(19):. PubMed ID: 28724768 [TBL] [Abstract][Full Text] [Related]
11. RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine. Jangra S; Laghlali G; Choi A; Rathnasinghe R; Chen Y; Yildiz S; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M Front Immunol; 2022; 13():974016. PubMed ID: 36426358 [TBL] [Abstract][Full Text] [Related]
12. Co-encapsulation of synthetic lipidated TLR4 and TLR7/8 agonists in the liposomal bilayer results in a rapid, synergistic enhancement of vaccine-mediated humoral immunity. Short KK; Miller SM; Walsh L; Cybulski V; Bazin H; Evans JT; Burkhart D J Control Release; 2019 Dec; 315():186-196. PubMed ID: 31654684 [TBL] [Abstract][Full Text] [Related]
13. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant. Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812 [TBL] [Abstract][Full Text] [Related]
14. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Xiao W; Du L; Liang C; Guan J; Jiang S; Lustigman S; He Y; Zhou Y Vaccine; 2008 Sep; 26(39):5022-9. PubMed ID: 18675867 [TBL] [Abstract][Full Text] [Related]
16. Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvant. Gray LT; Raczy MM; Briquez PS; Marchell TM; Alpar AT; Wallace RP; Volpatti LR; Sasso MS; Cao S; Nguyen M; Mansurov A; Budina E; Watkins EA; Solanki A; Mitrousis N; Reda JW; Yu SS; Tremain AC; Wang R; Nicolaescu V; Furlong K; Dvorkin S; Manicassamy B; Randall G; Wilson DS; Kwissa M; Swartz MA; Hubbell JA Biomaterials; 2021 Nov; 278():121159. PubMed ID: 34634664 [TBL] [Abstract][Full Text] [Related]
17. The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine. Donadei A; Balocchi C; Mancini F; Proietti D; Gallorini S; O'Hagan DT; D'Oro U; Berti F; Baudner BC; Adamo R Eur J Pharm Biopharm; 2016 Oct; 107():110-9. PubMed ID: 27388628 [TBL] [Abstract][Full Text] [Related]